ArticleCanadian journal of kidney health and disease2018
Gadolinium-Based Contrast Agents in Kidney Disease: A Comprehensive Review and Clinical Practice Guideline Issued by the Canadian Association of Radiologists.
Article in Canadian journal of kidney health and disease, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 50 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
50 citing papers in PubMed, 2 syntheses or guidelines pooled it, 109 citations in OpenAlex.
- Consensus guideline for the diagnosis and management of pituitary adenomas in childhood and adolescence: Part 1, general recommendations.Nature reviews. Endocrinology · 2024Guideline
- Risk of Nephrogenic Systemic Fibrosis in Patients With Stage 4 or 5 Chronic Kidney Disease Receiving a Group II Gadolinium-Based Contrast Agent: A Systematic Review and Meta-analysis.JAMA internal medicine · 2020Pooled it
- Microstructure imaging of prostate cancer by diffusion MRI.Magma (New York, N.Y.) · 2026Review
- Current Approaches to the Management of Acute Surgical and Medical Emergencies: A Structured Narrative Review.Cureus · 2026Review
- Article
- The Role of Cardiovascular Magnetic Resonance Imaging in Athletic Individuals-A Narrative Review.Journal of clinical medicine · 2025Review
- Detection of late gadolinium enhancement in patients with hypertrophic cardiomyopathy using machine learning.International journal of cardiology · 2025Article
- Blood-brain barrier breakdown in brain ischemia: Insights from MRI perfusion imaging.Neurotherapeutics : the journal of the American Society for Experimental NeuroTherapeutics · 2025Review
- Contralateral renal change in a unilateral ureteral obstruction rat model using intravoxel incoherent motion diffusion-weighted imaging.Renal failure · 2024Article
- Deep learning of echocardiography distinguishes between presence and absence of late gadolinium enhancement on cardiac magnetic resonance in patients with hypertrophic cardiomyopathy.Echo research and practice · 2024Article
- Gold Nanoparticle Transport in the Injured Kidneys with Elevated Renal Function Biomarkers.Advanced materials (Deerfield Beach, Fla.) · 2024Article
- Advances in the diagnosis of myocarditis in idiopathic inflammatory myopathies: an overview of diagnostic tests.Rheumatology (Oxford, England) · 2024Review
- Successful Embolization of a Direct Carotid Cavernous Fistula under Gadolinium-Based Angiography.Neurointervention · 2024Article
- X-ray and nuclear spectroscopies to reveal the element specific oxidation states and electronic spin states for nanoparticulated manganese cyanidoferrates and analogs.Physchem (Basel, Switzerland) · 2024Article
- Superfluorinated, Highly Water-Soluble Polyphosphazenes as PotentialJournal of functional biomaterials · 2024Article
- Contrast Agent-Free 3D Renal Ultrafast Doppler Imaging Reveals Vascular Dysfunction in Acute and Diabetic Kidney Diseases.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2023Article
- Reconstruction and Validation of Arterial Geometries for Computational Fluid Dynamics Using Multiple Temporal Frames of 4D Flow-MRI Magnitude Images.Cardiovascular engineering and technology · 2023Article
- Direct mapping of kidney function by DCE-MRI urography using a tetrazinanone organic radical contrast agent.Nature communications · 2023Article
- Non-invasive imaging techniques in patients with coronary chronic total occlusions: A key for successful diagnosis, revascularization, and post-intervention outcomes.Cardiology journal · 2023Article
- Current state of pediatric neuro-oncology imaging, challenges and future directions.Neoplasia (New York, N.Y.) · 2023Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
12 authors at 7 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
purpose of reviewUse of gadolinium-based contrast agents (GBCA) in renal impairment is controversial, with physician and patient apprehension in acute kidney injury (AKI), chronic kidney disease (CKD), and dialysis because of concerns regarding nephrogenic systemic fibrosis (NSF). The position that GBCA are absolutely contraindicated in AKI, category G4 and G5 CKD (estimated glomerular filtration rate [eGFR] < 30 mL/min/1.73 m SOURCES OF INFORMATION: Published literature (including clinical trials, retrospective cohort series, review articles, and case reports), online registries, and direct manufacturer databases were searched for reported cases of NSF by class and specific GBCA and exposed patient population.
methodsA comprehensive review was conducted identifying cases of NSF and their association to class of GBCA, specific GBCA used, patient, and dose (when this information was available). Based on the available literature, consensus guidelines were developed by an expert panel of radiologists and nephrologists. KEY
findingsIn patients with category G2 or G3 CKD (eGFR ≥ 30 and < 60 mL/min/1.73 m LIMITATIONS: Limited available literature (number of injections and use in renal impairment) regarding the use of gadoxetate disodium. Limited, but growing and generally high-quality, number of clinical trials evaluating GBCA administration in renal impairment. Limited data regarding the topic of Gadolinium deposition in the brain, particularly as it related to patients with renal impairment. IMPLICATIONS: In patients with AKI and category G4 and G5 CKD (eGFR < 30 mL/min/1.73 m
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.